Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL -24.94%17 3-Year ROIIC % is 96.12 as of Jun. 2025, which is at its 10-year median of 96.12. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 618 Healthcare Providers & Services companies, Basel Medical Group ranks better than 88.83% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Basel Medical Group's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 96.12%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Basel Medical Group's 3-Year ROIIC % or its related term are showing as below:
BMGL's 3-Year ROIIC % is ranked better than 88.83% of 618
companies
in the Healthcare Providers & Services industry
Industry Median: 3.37
vs BMGL: 96.12
Basel Medical Group (NAS:BMGL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Basel Medical Group 3-Year ROIIC % Related Terms
Basel Medical Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMGL vs AMS, HLYK, BICX: 3-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Basel Medical Group (BMGL) has a 3-Year ROIIC % of 96.12 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Basel Medical Group and its competitors. This is near median its historical median of 96.12. Over the past decade, Basel Medical Group's 3-Year ROIIC % has ranged from 96.12 to 96.12. According to the industry distribution chart, Basel Medical Group ranks #69 out of 618 companies in the Healthcare Providers & Services industry, placing it in the top 11.2%.
Is Basel Medical Group's 3-Year ROIIC % too high?
Basel Medical Group's current 3-Year ROIIC % of 96.12 is near median its 10-year median of 96.12. Over the past 10 years, this metric has ranged from a low of 96.12 to a high of 96.12. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.37. Basel Medical Group's value of 96.12 is 2752.2% above this industry median. Based on the distribution chart, Basel Medical Group ranks #69 out of 618 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's 3-Year ROIIC % compare to AMS and HLYK?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #69 out of 618 companies for 3-Year ROIIC %. This places Basel Medical Group in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.37. Basel Medical Group's value of 96.12 is 2752.2% above this benchmark. Historically, Basel Medical Group's own 3-Year ROIIC % has ranged from 96.12 to 96.12 over the past decade. While the company's 10-year median is 96.12 vs. the industry median of 3.37, Basel Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.37, based on 618 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basel Medical Group's current 3-Year ROIIC % of 96.12 is 2752.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current 3-Year ROIIC % is 96.12, which is near median its own 10-year median of 96.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current 3-Year ROIIC % of 96.12. The current 3-Year ROIIC % is 96.12, which is near median its 10-year median of 96.12 and 2752.2% above the Healthcare Providers & Services industry median of 3.37. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current 3-Year ROIIC % is 96.12 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
